{
    "id": "7e6e45d4-9266-4451-b6b6-0d054bbcab63",
    "indications": "cresemba ® azole antifungal indicated treatment : invasive aspergillosis ( 1.1 ) invasive mucormycosis ( 1.2 ) follows : • cresemba injection : adults pediatric patients 1 year age older • cresemba capsules : adults pediatric patients 6 years age older weigh 16 kilograms ( kg ) greater",
    "contraindications": "important instructions : • cresemba injection intended patients 1 year age older ( 2.1 , 2.3 ) . • cresemba injection via nasogastric ( ng ) tube intended patients 6 years age older weighing 16 kg greater . ( 2.1 , 2.6 ) . • cresemba injection must administered in-line filter minimum 1 hour . ( 2.1 , 2.5 ) . • cresemba capsules intended patients 6 years age older weighing 16 kg greater ( 2.1 , 2.3 ) . • cresemba capsules taken without food . ( 2.1 ) . recommended adult patients ( 2.2 ) : recommended cresemba adult patients ( 2.2 ) form loading dose maintenance dose start maintenance doses 12 24 hours last loading dose cresemba injection , 372 mg/vial 372 mg isavuconazonium sulfate per vial one reconstituted vial ( 372 mg ) intravenously every 8 hours 6 doses ( 48 hours ) one reconstituted vial ( 372 mg ) intravenously daily cresemba capsules , 186 mg 186 mg isavuconazonium sulfate per capsule two 186 mg capsules ( 372 mg ) orally every 8 hours 6 doses ( 48 hours ) two 186 mg capsules ( 372 mg ) orally daily cresemba capsules , 74.5 mg 74.5 mg isavuconazonium sulfate per capsule five 74.5 mg capsules ( 372 mg ) orally every 8 hours 6 doses ( 48 hours ) five 74.5 mg capsules ( 372 mg ) orally daily recommended pediatric patients ( 2.3 ) : • maximum individual loading daily maintenance dose administered pediatric patient 372 mg cresemba . ( 2.3 ) recommended cresemba pediatric patients ( 2.3 ) form age body weight ( kg ) loading dose maintenance dose start maintenance doses 12 24 hours last loading dose cresemba injection , 372 mg/vial 372 mg isavuconazonium sulfate per vial 1 less 3 years age less 18 kg 15 mg/kg intravenously every 8 hours 6 doses ( 48 hours ) 15 mg/kg intravenously daily 3 less 18 years age less 37 kg 10 mg/kg intravenously every 8 hours 6 doses ( 48 hours ) 10 mg/kg intravenously daily greater equal 37 kg one reconstituted vial ( 372 mg ) intravenously every 8 hours 6 doses ( 48 hours ) one reconstituted vial ( 372 mg ) intravenously daily cresemba capsules , 74.5 mg 74.5 mg isavuconazonium sulfate per capsule 6 less 18 years age 16 kg less 18 kg two capsules ( 149 mg ) orally every 8 hours 6 doses ( 48 hours ) two capsules ( 149 mg ) orally daily 18 kg less 25 kg three capsules ( 223.5 mg ) orally every 8 hours 6 doses ( 48 hours ) three capsules ( 223.5 mg ) orally daily 25 kg less 32kg four capsules ( 298 mg ) orally every 8 hours 6 doses ( 48 hours ) four capsules ( 298 mg ) orally daily greater equal 32 kg five 74.5 mg capsules ( 372 mg ) orally every 8 hours 6 doses ( 48 hours ) five 74.5 mg capsules ( 372 mg ) orally daily",
    "adverseReactions": "•cresemba contraindicated persons known hypersensitivity isavuconazole . •coadministration strong cyp3a4 inhibitors , ketoconazole high-dose ritonavir ( 400 mg every 12 hours ) , cresemba contraindicated strong cyp3a4 inhibitors significantly increase plasma concentration isavuconazole [ ( 7 ) pharmacology ( 12.3 ) ] . •coadministration strong cyp3a4 inducers , rifampin , carbamazepine , st. john ’ wort , long acting barbiturates cresemba contraindicated strong cyp3a4 inducers significantly decrease plasma concentration isavuconazole [ ( 7 ) pharmacology ( 12.3 ) ] . •cresemba shortened qtc interval concentration-related manner . cresemba contraindicated patients familial short qt syndrome [ pharmacology ( 12.2 ) ] .",
    "ingredients": [
        {
            "name": "ISAVUCONAZONIUM SULFATE",
            "code": "31Q44514JV"
        }
    ],
    "organization": "Astellas Pharma US, Inc.",
    "name": "CRESEMBA",
    "effectiveTime": "20250425",
    "indications_original": "CRESEMBA ® is an azole antifungal indicated for the treatment of: Invasive aspergillosis ( 1.1 ) and Invasive mucormycosis ( 1.2 ) as follows: • CRESEMBA for injection : adults and pediatric patients 1 year of age and older • CRESEMBA capsules : adults and pediatric patients 6 years of age and older who weigh 16 kilograms (kg) and greater",
    "contraindications_original": "Important Administration Instructions: • CRESEMBA for injection is intended for use in patients who are 1 year of age and older ( 2.1 , 2.3 ). • CRESEMBA for injection via nasogastric (NG) tube administration is intended for use by patients who are 6 years of age and older and weighing 16 kg and greater. ( 2.1 , 2.6 ). • CRESEMBA for injection must be administered through an in-line filter over a minimum of 1 hour. ( 2.1 , 2.5 ). • CRESEMBA capsules are intended for use in patients who are 6 years of age and older and weighing 16 kg and greater ( 2.1 , 2.3 ). • CRESEMBA capsules can be taken with or without food. ( 2.1 ). Recommended Dosage in Adult Patients ( 2.2 ): Recommended Dosage for CRESEMBA in Adult Patients ( 2.2 ) Dosage Form Loading Dose Maintenance Dose Start maintenance doses 12 to 24 hours after the last loading dose CRESEMBA for Injection, 372 mg/vial 372 mg of isavuconazonium sulfate per vial One reconstituted vial (372 mg) intravenously every 8 hours for 6 doses (48 hours) One reconstituted vial (372 mg) intravenously once daily CRESEMBA Capsules, 186 mg 186 mg of isavuconazonium sulfate per capsule Two 186 mg capsules (372 mg) orally every 8 hours for 6 doses (48 hours) Two 186 mg capsules (372 mg) orally once daily CRESEMBA Capsules, 74.5 mg 74.5 mg of isavuconazonium sulfate per capsule Five 74.5 mg capsules (372 mg) orally every 8 hours for 6 doses (48 hours) Five 74.5 mg capsules (372 mg) orally once daily Recommended Dosage in Pediatric Patients ( 2.3 ): • The maximum of any individual loading or daily maintenance dose to be administered to any pediatric patient is 372 mg of CRESEMBA. ( 2.3 ) Recommended Dosage for CRESEMBA in Pediatric Patients ( 2.3 ) Dosage Form Age Body Weight (kg) Loading Dose Maintenance Dose Start maintenance doses 12 to 24 hours after the last loading dose CRESEMBA for Injection, 372 mg/vial 372 mg of isavuconazonium sulfate per vial 1 to less than 3 years of age less than 18 kg 15 mg/kg intravenously every 8 hours for 6 doses (48 hours) 15 mg/kg intravenously once daily 3 to less than 18 years of age less than 37 kg 10 mg/kg intravenously every 8 hours for 6 doses (48 hours) 10 mg/kg intravenously once daily greater than or equal to 37 kg One reconstituted vial (372 mg) intravenously every 8 hours for 6 doses (48 hours) One reconstituted vial (372 mg) intravenously once daily CRESEMBA Capsules, 74.5 mg 74.5 mg of isavuconazonium sulfate per capsule 6 to less than 18 years of age 16 kg to less than 18 kg Two capsules (149 mg) orally every 8 hours for 6 doses (48 hours) Two capsules (149 mg) orally once daily 18 kg to less than 25 kg Three capsules (223.5 mg) orally every 8 hours for 6 doses (48 hours) Three capsules (223.5 mg) orally once daily 25 kg to less than 32kg Four capsules (298 mg) orally every 8 hours for 6 doses (48 hours) Four capsules (298 mg) orally once daily greater than or equal to 32 kg Five 74.5 mg capsules (372 mg) orally every 8 hours for 6 doses (48 hours) Five 74.5 mg capsules (372 mg) orally once daily",
    "adverseReactions_original": "•CRESEMBA is contraindicated in persons with known hypersensitivity to isavuconazole.\n                     \n                        •Coadministration of strong CYP3A4 inhibitors, such as ketoconazole or high-dose ritonavir (400 mg every 12 hours), with CRESEMBA is contraindicated because strong CYP3A4 inhibitors can significantly increase the plasma concentration of isavuconazole [see Drug Interactions (7) and Clinical Pharmacology (\n                        12.3\n                        )].\n                     \n                        •Coadministration of strong CYP3A4 inducers, such as rifampin, carbamazepine, St. John’s wort, or long acting barbiturates with CRESEMBA is contraindicated because strong CYP3A4 inducers can significantly decrease the plasma concentration of isavuconazole [see Drug Interactions (7) and Clinical Pharmacology (\n                        12.3\n                        )].\n                     \n                        •CRESEMBA shortened the QTc interval in a concentration-related manner. CRESEMBA is contraindicated in patients with familial short QT syndrome [see Clinical Pharmacology (\n                        12.2\n                        )]."
}